“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|CMS Enters Pricey Hepatitis C Drug Debate|
Nov. 11, 2015
"The letters [sent by CMS to Medicaid directors of all 50 states and four drug manufacturers] were all related to the cost of those drugs, which can run upwards of $90,000 for the course of treatment.... CMS said it was interested in learning about what, if any, 'value-based' purchasing (VBP) arrangements are being offered to private plans and Medicaid plans. The agency said it thinks VBP arrangements may help get the best price for the drugs. CMS also warned against states limiting access to the drugs on the basis of cost."
|Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the link above).|
|An important word about authorship: BenefitsLink® is providing a hypertext link to the item shown above, but is not the author of the item (unless otherwise specified).|